Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 154 Brain Neoplasms 73 Glioma 69 Central Nervous System Neoplasms 50 Gliosarcoma 46 Astrocytoma 37 Melanoma 36 Oligodendroglioma 29 Neuroblastoma 17 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Sarcoma, Ewing 10 Sarcoma 10 Neoplasms 10 Medulloblastoma 10 Recurrence 9 Neuroendocrine Tumors 9 Lymphoma 8 Ependymoma 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Diffuse Intrinsic Pontine Glioma 7 Colorectal Neoplasms 7 Carcinoma, Neuroendocrine 6 Adenoma, Islet Cell 6 Uveal Melanoma 5 Spinal Cord Neoplasms 5 Pheochromocytoma 5

Interventions

Oxaliplatin 146 Fluorouracil 137 Capecitabine 122 Leucovorin 106 Irinotecan 85 Radiotherapy 67 Bevacizumab 64 Cetuximab 46 Folfox protocol 28 Surgical Procedures, Operative 23 Radiation 23 Drug Therapy 22 Panitumumab 19 XELOX 18 Chemotherapy, Adjuvant 15 Neoadjuvant Therapy 14 Radiotherapy, Intensity-Modulated 13 Chemoradiotherapy 13 Magnetic Resonance Spectroscopy 11 regorafenib 10 Nivolumab 10 Floxuridine 10 sintilimab 8 raltitrexed 8 Specimen Handling 8 IFL protocol 8 Celecoxib 8 Biopsy 8 trifluridine tipiracil drug combination 7 tislelizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rectal Neoplasms × Temozolomide × Clear all

NCT05136326 2023-03-01

CATARTIC

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡